Abstract
6 compounds developed by M4K Pharma to inhibit the ACVR1/ALK2 tyrosine kinase where tested for their ability to reduce viability of both mutant and wild-type ACVR1 DIPG cell lines (HSJD-DIPG-007 and HSJD-DIPG-011 respectively). Compounds where tested on cells grown as 2D sheets and 3D neurospheres, as well as with and without radiation treatment. M4K2009 was highly effective in ACVR1 mutant DIPG cells, but this was not the case in ACVR1 wild-type cells.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
